A phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel vs. placebo + Trastuzumab + Docetaxel in patients with previously untreated HER2-positive metastatic b
Concordance in Hormone Receptors and HER2 Expression between Primary Breast Cancer, Loco-Regional Recurrences and Distant Metastases. Subgroups Analysis and Predictors of Discordance. FE PETRACCI et al
Neoadjuvant chemotherapy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). G VON MINCKWITZ et al
Traitements antiHER2 en situation adjuvante. Quels produits ? quelles durées ? quelles chimiothérapies associer ?
Systemic Adjuvant Treatment of T1a and T1b N0M0 HER2 + Breast Carcinomas; an AERIO/UNICANCER Study (Abstract P2-18-03; Peron J et al.) et HER2 expression is the major risk factor for recurrence in pT1a-b, N0 breast cancer: a French regional population-bas
LECON 1 : La génomique a un coût. Comment peut-on la faire prendre en charge ? L’expérience bisontine avec Oncotype Dx
